Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

What is required to advance data ethics, data sharing, and Open Science across...

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India

What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating...

Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma ( Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan )

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )

Cancer survivors' stories: An African perspective

Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation

Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

A new era of early cancer detection with blood test may change cancer screening...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer